Abiopharma

🔍 McRaven William H. (Executive)

Company: CONOCOPHILLIPS (COP)

Report Date: 2026-04-15

Detailed Transactions and Holdings:

• Acquired 2,230 shares of Common Stock (Direct)
  Date: 2026-04-15 | Code: M | equity_swap_involved: false | shares_owned_after: 8,096.50 | transaction_form_type: 4 | Footnotes: F1, F2
• Acquired 2,230 shares of Stock Units (Derivative)
  Date: 2026-04-15 | Code: M | equity_swap_involved: false | shares_owned_after: 23,537.00 | transaction_form_type: 4 | Footnotes: F3, F4, F4, F2

Footnotes:

• F1: Each stock unit was the economic equivalent of one share of common stock and settled in shares.
• F2: Includes units acquired through routine dividend transactions that are exempt under rule 16a-11.
• F3: The stock units represent ConocoPhillips common stock on a 1-for-1 basis.
• F4: The reporting person has elected to receive payment as a lump sum three months from initial grant date.